Securities ▲▼ | Shares | Value | |||||
|---|---|---|---|---|---|---|---|
Q3 2023 ▲▼ | Q4 2023 ▲▼ | Change ▲▼ | Q3 2023 ▲▼ | Q4 2023 ▲▼ | Weight (%) ▲▼ | Change ▲▼ | |
| Arcellx Inc. COMMON STOCK | 3,946,630 | 3,146,630 | -800,000 | $141.61M | $174.64M | 73.33% | +$33.03M |
| ARS Pharmaceuticals, Inc.(SPRY) | 4,012,903 | 4,012,903 | 0 | $15.17M | $21.99M | 9.23% | +$6.82M |
| Design Therapeutics, Inc.(DSGN) | 6,526,476 | 6,526,476 | 0 | $15.40M | $17.30M | 7.26% | +$1.89M |
| Mineralys Therapeutics, Inc.(MLYS) | 1,794,600 | 1,794,600 | 0 | $17.07M | $15.43M | 6.48% | -$1.63M |
| Nkarta, Inc.(NKTX) | 1,333,333 | 1,333,333 | 0 | $1.85M | $8.80M | 3.70% | +$6.95M |
| EFFECTOR THERAPEUTICS INCCOM | 6,822,114 | 0 | -6,822,114 | $4.03M | $0 | — | -$4.03M |